Trials / Completed
CompletedNCT02999711
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Effects of Subcutaneously Administered REGN3500 in Adult Patients With Moderate Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN3500 | REGN3500 dose |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2018-08-30
- Completion
- 2018-09-10
- First posted
- 2016-12-21
- Last updated
- 2018-12-12
Locations
3 sites across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02999711. Inclusion in this directory is not an endorsement.